Nasdaq:US$13.50 (+0.55) | HKEX:HK$22.05 (+0.25) | AIM:£2.26 (+0.09)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
IN-LICENSED PRODUCT
LAUNCHED IN CHINA
HAINAN PILOT ZONE
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
4,900
PERSONNEL ACROSS
THE GROUP

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


Deutsche Bank ADR Virtual Investor Conference (dbVIC) 2022-11-17
Corporate Presentation for Investors 2022-11-15
Goldman Sachs Asia Pacific Healthcare Forum 2022 2022-11-14 - 2022-11-18